Kristyn Galbraith
Overview
Explore the profile of Kristyn Galbraith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
163
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Galbraith K, Wu J, Sikkink K, Mohamed H, Reid D, Perez-Arreola M, et al.
J Mol Diagn
. 2025 Mar;
PMID: 40023492
Chromosomal structural variants (SVs) are major contributors to cancer development. Although multiple methods exist for detecting SVs, they are limited in throughput, such as fluorescent in situ hybridization and targeted...
2.
Walker A, Fang C, Schroff C, Serrano J, Vasudevaraja V, Yang Y, et al.
J Neuropathol Exp Neurol
. 2024 Nov;
84(2):147-154.
PMID: 39607989
Cancer of unknown primary (CUP) constitutes between 2% and 5% of human malignancies and is among the most common causes of cancer death in the United States. Brain metastases are...
3.
Karz A, Coudray N, Bayraktar E, Galbraith K, Jour G, Shadaloey A, et al.
Pigment Cell Melanoma Res
. 2024 Sep;
38(1):e13195.
PMID: 39254030
As efforts to study the mechanisms of melanoma metastasis and novel therapeutic approaches multiply, researchers need accurate, high-throughput methods to evaluate the effects on tumor burden resulting from specific interventions....
4.
Fang C, Wang W, Schroff C, Movahed-Ezazi M, Vasudevaraja V, Serrano J, et al.
Neurooncol Adv
. 2024 Sep;
6(1):vdae135.
PMID: 39220243
Background: In many cancers, specific subtypes are more prevalent in specific racial backgrounds. However, little is known about the racial distribution of specific molecular types of brain tumors. Public data...
5.
Lee M, Jain R, Galbraith K, Chen A, Lieberman E, Patel S, et al.
Clin Cancer Res
. 2024 Jun;
30(16):3512-3519.
PMID: 38829583
Purpose: DNA methylation profiling stratifies isocitrate dehydrogenase (IDH)-mutant astrocytomas into methylation low- and high-grade groups. We investigated the utility of the T2-fluid-attenuated inversion recovery (T2-FLAIR) mismatch sign for predicting DNA...
6.
Galbraith K, Snuderl M
Clin Lab Med
. 2024 May;
44(2):149-159.
PMID: 38821638
Gliomas are the most common adult and pediatric primary brain tumors. Molecular studies have identified features that can enhance diagnosis and provide biomarkers. IDH1/2 mutation with ATRX and TP53 mutations...
7.
Galbraith K, Garcia M, Wei S, Chen A, Schroff C, Serrano J, et al.
Neuro Oncol
. 2024 Jan;
26(6):1042-1051.
PMID: 38243818
Background: Isocitrate dehydrogenase (IDH) mutant astrocytoma grading, until recently, has been entirely based on morphology. The 5th edition of the Central Nervous System World Health Organization (WHO) introduces CDKN2A/B homozygous...
8.
McCord M, Jamshidi P, Thirunavu V, Santana-Santos L, Vormittag-Nocito E, Dittman D, et al.
Acta Neuropathol Commun
. 2023 Nov;
11(1):175.
PMID: 37919784
MGMT promoter methylation testing is required for prognosis and predicting temozolomide response in gliomas. Accurate results depend on sufficient tumor cellularity, but histologic estimates of cellularity are subjective. We sought...
9.
Galbraith K, Serrano J, Shen G, Tran I, Slocum C, Ketchum C, et al.
Mol Cancer Res
. 2023 Oct;
22(1):21-28.
PMID: 37870438
Implications: DNA methylation signatures need to be interpreted in the context of pathology and discordant results warrant testing for novel and rare gene fusions.
10.
Galbraith K, Vasudevaraja V, Serrano J, Shen G, Tran I, Abdallat N, et al.
Neurooncol Adv
. 2023 Jul;
5(1):vdad076.
PMID: 37476329
Background: Central nervous system (CNS) cancer is the 10th leading cause of cancer-associated deaths for adults, but the leading cause in pediatric patients and young adults. The variety and complexity...